Lack of evidence for involvement of P-glycoprotein in brain uptake of the centrally acting analgesic, tramadol in the rat

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 5, 2012, Pages 606-615

  Sheikholeslami, Behjat ^a   Hamidi, Mehrdad ^b   Lavasani, Hoda ^a   Sharifzadeh, Mohammad ^a   Rouini, Mohammad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; TRAMADOL; VERAPAMIL;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; IC 50; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84869444739     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3d60r     Document Type: Article

References (38)

1. Doze P, Van Waarde A, Elsinga PH, Hendrikse NH, Vaalburg W. Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier. Synapse,2000; 36: 66-74.
2. Lai CH, Kuo KH, Leo JM. Critical role of actin in modulating BBB permeability. Brain Res Brain Res Rev, 2005; 50: 7-13.
3. Guofeng Y, Marilyn EM, Binghe W. Drug Transporters: Molecular Characterization and Role in Drug Disposition. Wiley-Interscience: New York, 2007.
4. Hammarlund-Udenaes M, Paalzow LK, de Lange EC. Drug equilibration across the blood-brain barrier--pharmacokinetic considerations based on the microdialysis method. Pharm Res, 1997; 14: 128-134.
5. Syvänen S, Xie R, Sahin S, Hammarlund-Udenaes M. Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharm Res, 2006; 23: 705-717.
6. Golden PL, Pollack GM. Rationale for influx enhancement versus efflux blockade to increase drug exposure to the brain. Biopharm Drug Dispos, 1998; 19: 263-272.
7. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev, 2003; 55: 425-461.
8. Brinkmann U. Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P glycoprotein expression and activity in vivo. Novartis Found Symp, 2002; 243: 207-210.
9. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci, 2004; 25: 423-429.
10. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest, 2003; 33 (Suppl. 2): 6-9.
11. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol, 1997; 40 (Suppl.): S3-S8.
12. Lee G, Dallas S, Hong M, Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev, 2001; 53: 569-596.
13. Hamidi M. Role of P-glycoprotein in tissue uptake of indinavir in rat. Life Sci, 2006; 79: 991-998.
14. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev, 2003; 55: 3-29.
15. Uhr M, Grauer MT. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res, 2003; 37: 179-185.
16. Uhr M, Grauer MT, Yassouridis A, Ebinger M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knockout mice and controls. J Psychiatr Res, 2007; 41: 179-188.
17. Karlsson L, Schmitt U, Josefsson M, Carlsson B, Ahlner J, Bengtsson F, Kugelberg FC, Hiemke C. Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Eur Neuropsychopharmacol, 2010; 20: 632-640.
18. Dayer P, Collart L, Desmeules J. The pharmacology of tramadol. Drugs, 1994; 47 (Suppl 1): 3-7.
19. Poulsen L, Arendt-Nielsen L, Brøsen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther, 1996; 60: 636-644.
20. Budd K, Langford R. Tramadol revisited. Br J Anaesth, 1999; 82: 493-495.
21. Seelig A, Landwojtowicz E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci, 2000; 12: 31-40.
22. Kanaan M, Daali Y, Dayer P, Desmeules J. Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on Pglycoprotein. Basic Clin Pharmacol Toxicol, 2009; 105: 199-206.
23. Slanar O, Nobilis M, Kvétina J, Matousková O, Idle JR, Perlík F. Pharmacokinetics of tramadol is affected by MDR1 polymorphism C3435T. Eur J Clin Pharmacol, 2007; 63: 419-421.
24. Waynforth HB, Flecknell PA. Experimental and Surgical Techniques in the Rat, 2nd edn. Academic Press: London, 1992.
25. Ardakani YH, Rouini MR. Improved liquid chromatographic method for the simultaneous determination of tramadol and its three main metabolites in human plasma, urine and saliva. J Pharm Biomed Anal, 2007; 44: 1168-1173.
26. Shargel L, Wu-PongS, Yu A. Applied Biopharmaceutics and Pharmacokinetics, 5th edn. McGraw-Hill Medical: New York, 2004.
27. Hamidi M. Central nervous system distribution kinetics of indinavir in rats. J Pharm Pharmacol, 2007; 59: 1077-1085.
28. Tao Q, Stone DJ, Borenstein MR, Codd EE, Coogan TP, Desai-Krieger D, Liao S, Raffa RB. Differential tramadol and O-desmethyl metabolite levels in brain vs. plasma of mice and rats administered tramadol hydrochloride orally. J Clin Pharm Ther, 2002; 27: 99-106.
29. Allegaert K, de Hoon J, Verbesselt R, Devlieger H, Tibboel D. Tramadol concentrations in blood and in cerebrospinal fluid in a neonate. Eur J Clin Pharmacol, 2005; 60: 911-913.
30. Sakugawa T, Miura M, Hokama N, Suzuki T, Tateishi T, Uno T. Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. Br J Clin Pharmacol, 2009; 67: 535-40.
31. Bansal T, Mishra G, Jaggi M, Khar RK, Talegaonkar S. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci, 2009; 36: 580-590.
32. Choi JS, Li X. The effect of verapamil on the pharmacokinetics of paclitaxel in rats. Eur J Pharm Sci, 2005; 24: 95-100.
33. Marier JF, Deschênes JL, Hage A, Seliniotakis E, Gritsas A, Flarakos T, Beaudry F, Vachon P. Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil. Life Sci, 2005; 77: 2911-2926.
34. Cisternino S, Bourasset F, Archimbaud Y, Sémiond D, Sanderink G, Scherrmann JM. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of Pglycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol, 2003; 138: 1367-1375.
35. Zolnerciks JK, Booth-Genthe CL, Gupta A, Harris J, Unadkat JD. Substrate-and speciesdependent inhibition of P-glycoprotein-mediated transport: implications for predicting in vivo drug interactions. J Pharm Sci, 2011; 100: 3055-3061.
36. Sahraei MA. Role of P-glycoprotein in neuropharmacokinetic of phenytoin in rat. Pharm. D. Thesis, No. 287, faculty of pharmacy, Shiraz university of medical sciences, Shiraz, Iran. 2006
37. Majidi L. effect of acute and chronic inflammation on the functional role Pglycoprotein in Blood-Brain Barrier. Pharm. D. Thesis, No. 328, faculty of pharmacy, Shiraz university of medical sciences, Shiraz, Iran. 2010.
38. Aryanpour Z. The effect of P-glycoprotein on neuropharmacokinetic of phenytoin at acute seizure rat. Pharm. D. Thesis, No. 357, faculty of pharmacy, Shiraz university of medical sciences, Shiraz, Iran. 2009.